Specifying protein kinase C functions in melanoma

Pigment Cell and Melanoma Research

Volumn 25, Issue 4, 2012, Pages 466-476

  Denning, Mitchell F ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Melanocyte; Protein kinase C; Signal transduction

Indexed keywords

BRYOSTATIN; BRYOSTATIN 1; ENZASTAURIN; INGENOL MEBUTATE; PROTEIN KINASE C; PROTEIN KINASE C BETA; PROTEIN SERINE THREONINE KINASE; VEMURAFENIB;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; BINDING SITE; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; MELANOCYTE; MELANOMA; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE;

ANIMALS; ENZYME ACTIVATORS; GENETIC HETEROGENEITY; HUMANS; MELANOMA; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; SKIN NEOPLASMS;

EID: 84862703651     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2012.01015.x     Document Type: Review

References (144)

1. Albelda, S.M., Mette, S.A., Elder, D.E., Stewart, R., Damjanovich, L., Herlyn, M., and Buck, C.A. (1990). Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res. 50, 6757-6764.
2. Anderson, L., Schmieder, G.J., Werschler, W.P., Tschen, E.H., Ling, M.R., Stough, D.B., and Katsamas, J. (2009). Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J. Am. Acad. Dermatol. 60, 934-943.
3. Arita, Y., O'Driscoll, K.R., and Weinstein, I.B. (1992). Growth of human melanocyte cultures supported by 12-O-tetradecanoylphorbol-13-acetate is mediated through protein kinase C activation. Cancer Res. 52, 4514-4521.
4. Arita, Y., O'Driscoll, K.R., and Weinstein, I.B. (1994). Growth inhibition of human melanoma-derived cells by 12-O-tetradecanoyl phorbol 13-acetate. Int. J. Cancer 56, 229-235.
5. Aziz, M.H., Manoharan, H.T., Church, D.R., Dreckschmidt, N.E., Zhong, W., Oberley, T.D., Wilding, G., and Verma, A.K. (2007a). Protein kinase Cε interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. Cancer Res. 67, 8828-8838.
6. Aziz, M.H., Manoharan, H.T., and Verma, A.K. (2007b). Protein kinase C ε, which sensitizes skin to sun's UV radiation-induced cutaneous damage and development of squamous cell carcinomas, associates with Stat3. Cancer Res. 67, 1385-1394.
7. Bedikian, A.Y., Plager, C., Stewart, J.R., O'Brian, C.A., Herdman, S.K., Ross, M., Papadopoulos, N., Eton, O., Ellerhorst, J., and Smith, T. (2001). Phase II evaluation of bryostatin-1 in metastatic melanoma. Melanoma Res. 11, 183-188.
8. Benavides, F., Blando, J., Perez, C.J., Garg, R., Conti, C.J., DiGiovanni, J., and Kazanietz, M.G. (2011). Transgenic overexpression of PKCepsilon in the mouse prostate induces preneoplastic lesions. Cell Cycle 10, 268-277.
9. Benes, C.H., Wu, N., Elia, A.E., Dharia, T., Cantley, L.C., and Soltoff, S.P. (2005). The C2 domain of PKCδ is a phosphotyrosine binding domain. Cell 121, 271-280.
10. Bittner, M., Meltzer, P., Chen, Y. et al. (2000). Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536-540.
11. Byers, H.R., Boissel, S.J., Tu, C., and Park, H.Y. (2010). RNAi-mediated knockdown of protein kinase C-alpha inhibits cell migration in MM-RU human metastatic melanoma cell line. Melanoma Res. 20, 171-178.
12. Carducci, M.A., Musib, L., Kies, M.S. et al. (2006). Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J. Clin. Oncol. 24, 4092-4099.
13. Chen, X., and Rotenberg, S.A. (2010). PhosphoMARCKS drives motility of mouse melanoma cells. Cell Signal. 22, 1097-1103.
14. Churchill, E.N., Qvit, N., and Mochly-Rosen, D. (2009). Rationally designed peptide regulators of protein kinase C. Trends Endocrinol. Metab. 20, 25-33.
15. Cohen, E.E., Lingen, M.W., Zhu, B., Zhu, H., Straza, M.W., Pierce, C., Martin, L.E., and Rosner, M.R. (2006). Protein kinase Cζ mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res. 66, 6296-6303.
16. Cozzi, S.J., Parsons, P.G., Ogbourne, S.M., Pedley, J., and Boyle, G.M. (2006). Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway. Cancer Res. 66, 10083-10091.
17. D'Costa, A.M., Robinson, J.K., Maududi, T., Chaturvedi, V., Nickoloff, B.J., and Denning, M.F. (2006). The proapoptotic tumor suppressor protein kinase C-δ is lost in human squamous cell carcinomas. Oncogene 25, 378-386.
18. DelCarlo, M., and Loeser, R.F. (2006). Chondrocyte cell death mediated by reactive oxygen species-dependent activation of PKC-βI. Am. J. Physiol. Cell Physiol. 290, C802-C811.
19. Denning, M.F., Dlugosz, A.A., Howett, M.K., and Yuspa, S.H. (1993). Expression of an oncogenic rasHa gene in murine keratinocytes induces tyrosine phosphorylation and reduced activity of protein kinase C δ. J. Biol. Chem. 268, 26079-26081.
20. Denning, M.F., Wang, Y., Nickoloff, B.J., and Wrone-Smith, T. (1998). Protein kinase Cδ is activated by caspase-dependent proteolysis during ultraviolet radiation-induced apoptosis of human keratinocytes. J. Biol. Chem. 273, 29995-30002.
21. Denning, M.F., Wang, Y., Tibudan, S., Nickoloff, B.J., and Qin, J.Z. (2002). Caspase activation and disruption of mitochondrial membrane potential during UV radiation-induced apoptosis of human keratinocyte requires activation of protein kinase C. Cell Death Differ. 9, 40-52.
22. DeVries, T.A., Neville, M.C., and Reyland, M.E. (2002). Nuclear import of PKCδ is required for apoptosis: identification of a novel nuclear import sequence. EMBO J. 21, 6050-6060.
23. Dissanayake, S.K., Wade, M., Johnson, C.E. et al. (2007). The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J. Biol. Chem. 282, 17259-17271.
24. Dissanayake, S.K., Olkhanud, P.B., O'Connell, M.P. et al. (2008). Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res. 68, 10205-10214.
25. Eisinger, M., and Marko, O. (1982). Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin. Proc. Natl. Acad. Sci. U.S.A. 79, 2018-2022.
26. Eisinger, M., Marko, O., and Weinstein, I.B. (1983). Stimulation of growth of human melanocytes by tumor promoters. Carcinogenesis 4, 779-781.
27. Emoto, Y., Manome, Y., Meinhardt, G. et al. (1995). Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO J. 14, 6148-6156.
28. Faul, M.M., Gillig, J.R., Jirousek, M.R., Ballas, L.M., Schotten, T., Kahl, A., and Mohr, M. (2003). Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCβ. Bioorg. Med. Chem. Lett. 13, 1857-1859.
29. Feldman, R.I., Wu, J.M., Polokoff, M.A. et al. (2005). Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J. Biol. Chem. 280, 19867-19874.
30. Flaherty, K.T., Puzanov, I., Kim, K.B. et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
31. Fried, L., and Arbiser, J.L. (2008). The reactive oxygen-driven tumor: relevance to melanoma. Pigment Cell Melanoma Res. 21, 117-122.
32. Garraway, L.A., Widlund, H.R., Rubin, M.A. et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122.
33. Gilhooly, E.M., Morse-Gaudio, M., Bianchi, L., Reinhart, L., Rose, D.P., Connolly, J.M., Reed, J.A., and Albino, A.P. (2001). Loss of expression of protein kinase C β is a common phenomenon in human malignant melanoma: a result of transformation or differentiation? Melanoma Res. 11, 355-369.
34. Gillespie, S.K., Zhang, X.D., and Hersey, P. (2004). Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells. Mol. Cancer Ther. 3, 1651-1658.
35. Giorgio, M., Migliaccio, E., Orsini, F. et al. (2005). Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 122, 221-233.
36. Gonzalez, R., Ebbinghaus, S., Henthorn, T.K., Miller, D., and Kraft, A.S. (1999). Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study. Melanoma Res. 9, 599-606.
37. Gorden, A., Osman, I., Gai, W., He, D., Huang, W., Davidson, A., Houghton, A.N., Busam, K., and Polsky, D. (2003). Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res. 63, 3955-3957.
38. Govindarajan, B., Sligh, J.E., Vincent, B.J. et al. (2007). Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J. Clin. Invest. 117, 719-729.
39. Graff, J.R., McNulty, A.M., Hanna, K.R. et al. (2005). The protein kinase Cβ-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 65, 7462-7469.
40. Guldberg, P., thor, S.P., Birck, A., Ahrenkiel, V., Kirkin, A.F., and Zeuthen, J. (1997). Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57, 3660-3663.
41. Hampson, P., Chahal, H., Khanim, F., Hayden, R., Mulder, A., Assi, L.K., Bunce, C.M., and Lord, J.M. (2005). PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood 106, 1362-1368.
42. Hanauske, A.R., Oberschmidt, O., Hanauske-Abel, H., Lahn, M.M., and Eismann, U. (2007). Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro [corrected] soft-agar cloning experiments. Invest. New Drugs 25, 205-210.
43. Hatzivassiliou, G., Song, K., Yen, I. et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435.
44. Hennings, H., Blumberg, P.M., Pettit, G.R., Herald, C.L., Shores, R., and Yuspa, S.H. (1987). Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis 8, 1343-1346.
45. Hirai, T., and Chida, K. (2003). Protein kinase Cζ (PKCζ): activation mechanisms and cellular functions. J. Biochem. 133, 1-7.
46. Hirobe, T. (2001). Endothelins are involved in regulating the proliferation and differentiation of mouse epidermal melanocytes in serum-free primary culture. J. Invest. Dermatol. Symp. Proc. 6, 25-31.
47. Hoek, K., Rimm, D.L., Williams, K.R. et al. (2004). Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res. 64, 5270-5282.
48. Hoshi, N., Langeberg, L.K., Gould, C.M., Newton, A.C., and Scott, J.D. (2010). Interaction with AKAP79 modifies the cellular pharmacology of PKC. Mol. Cell 37, 541-550.
49. Imokawa, G., Kobayashi, T., Miyagishi, M., Higashi, K., and Yada, Y. (1997). The role of endothelin-1 in epidermal hyperpigmentation and signaling mechanisms of mitogenesis and melanogenesis. Pigment Cell Res. 10, 218-228.
50. Johannessen, C.M., Boehm, J.S., Kim, S.Y. et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972.
51. Kazanietz, M.G. (2000). Eyes wide shut: protein kinase C isozymes are not the only receptors for the phorbol ester tumor promoters. Mol. Carcinog. 28, 5-11.
52. Kazanietz, M.G., Areces, L.B., Bahador, A., Mischak, H., Goodnight, J., Mushinski, J.F., and Blumberg, P.M. (1993). Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C isozymes. Mol. Pharmacol. 44, 298-307.
53. Keyes, K.A., Mann, L., Sherman, M., Galbreath, E., Schirtzinger, L., Ballard, D., Chen, Y.F., Iversen, P., and Teicher, B.A. (2004). LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother. Pharmacol 53, 133-140.
54. Kim, J.D., Seo, K.W., Lee, E.A., Quang, N.N., Cho, H.R., and Kwon, B. (2011). A novel mouse PKCdelta splice variant, PKCdeltaIX, inhibits etoposide-induced apoptosis. Biochem. Biophys. Res. Commun. 410, 177-182.
55. Klauck, T.M., Faux, M.C., Labudda, K., Langeberg, L.K., Jaken, S., and Scott, J.D. (1996). Coordination of three signaling enzymes by AKAP79, a mammalian scaffold protein. Science 271, 1589-1592.
56. Lau, E., Kluger, H., Varsano, T., Lee, K., Scheffler, I., Rimm, D.L., Ideker, T., and Ronai, Z.A. (2012). PKCε promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Cell 148, 543-555.
57. Lewis, J.M., Cheresh, D.A., and Schwartz, M.A. (1996). Protein kinase C regulates alpha v beta 5-dependent cytoskeletal associations and focal adhesion kinase phosphorylation. J. Cell Biol. 134, 1323-1332.
58. Li, L., Lorenzo, P.S., Bogi, K., Blumberg, P.M., and Yuspa, S.H. (1999). Protein kinase C δ targets mitochondria, alters mitochondrial membrane potential, and induces apoptosis in normal and neoplastic keratinocytes when overexpressed by an adenoviral vector. Mol. Cell. Biol. 19, 8547-8558.
59. Li, L., Shukla, S., Lee, A., Garfield, S.H., Maloney, D.J., Ambudkar, S.V., and Yuspa, S.H. (2010). The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res. 70, 4509-4519.
60. Lopez-Bergami, P., Habelhah, H., Bhoumik, A., Zhang, W., Wang, L.H., and Ronai, Z. (2005). RACK1 mediates activation of JNK by protein kinase C. Mol. Cell 19, 309-320.
61. Lopez-Bergami, P., Huang, C., Goydos, J.S. et al. (2007). Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 11, 447-460.
62. Lopez-Bergami, P., Kim, H., Dewing, A., Goydos, J., Aaronson, S., and Ronai, Z. (2010). c-Jun regulates phosphoinositide-dependent kinase 1 transcription: implication for Akt and protein kinase C activities and melanoma tumorigenesis. J. Biol. Chem. 285, 903-913.
63. Lozano, J., Berra, E., Municio, M.M., Diaz-Meco, M.T., Dominguez, I., Sanz, L., and Moscat, J. (1994). Protein kinase C ζ isoform is critical for κB-dependent promoter activation by sphingomyelinase. J. Biol. Chem. 269, 19200-19202.
64. Lu, Z., Cox-Hipkin, M.A., Windsor, W.T., and Boyapati, A. (2010). 3-phosphoinositide-dependent protein kinase-1 regulates proliferation and survival of cancer cells with an activated mitogen-activated protein kinase pathway. Mol. Cancer Res. 8, 421-432.
65. Mackay, H.J., and Twelves, C.J. (2007). Targeting the protein kinase C family: are we there yet? Nat. Rev. Cancer 7, 554-562.
66. Marin, Y.E., Namkoong, J., Cohen-Solal, K., Shin, S.S., Martino, J.J., Oka, M., and Chen, S. (2006). Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCε. Cell. Signal. 18, 1279-1286.
67. Mason, S.A., Cozzi, S.J., Pierce, C.J., Pavey, S.J., Parsons, P.G., and Boyle, G.M. (2009). The induction of senescence-like growth arrest by protein kinase C-activating diterpene esters in solid tumor cells. Invest. New Drugs 28, 575-586.
68. Meyskens Jr, F.L., McNulty, S.E., Buckmeier, J.A., Tohidian, N.B., Spillane, T.J., Kahlon, R.S., and Gonzalez, R.I. (2001). Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes. Free Radic. Biol. Med. 31, 799-808.
69. Mhaidat, N.M., Thorne, R.F., Zhang, X.D., and Hersey, P. (2007). Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C. Mol. Cancer Res. 5, 1073-1081.
70. Mhaidat, N.M., Thorne, R., Zhang, X.D., and Hersey, P. (2008). Involvement of endoplasmic reticulum stress in Docetaxel-induced JNK-dependent apoptosis of human melanoma. Apoptosis 13, 1505-1512.
71. Mirmohammadsadegh, A., Marini, A., Nambiar, S., Hassan, M., Tannapfel, A., Ruzicka, T., and Hengge, U.R. (2006). Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 66, 6546-6552.
72. Mufson, R.A., Fischer, S.M., Verma, A.K., Gleason, G.L., Slaga, T.J., and Boutwell, R.K. (1979). Effects of 12-O-tetradecanoylphorbol-13-acetate and mezerein on epidermal ornithine decarboxylase activity, isoproterenol-stimulated levels of cyclic adenosine 3′:5′-monophosphate, and induction of mouse skin tumors in vivo. Cancer Res. 39, 4791-4795.
73. Muller, G., Ayoub, M., Storz, P., Rennecke, J., Fabbro, D., and Pfizenmaier, K. (1995). PKCζ is a molecular switch in signal transduction of TNF-α, bifunctionally regulated by ceramide and arachidonic acid. EMBO J. 14, 1961-1969.
74. Nakanishi, H., Brewer, K.A., and Exton, J.H. (1993). Activation of the ζ isozyme of protein kinase C by phosphatidylinositol 3, 4, 5-trisphosphate. J. Biol. Chem. 268, 13-16.
75. Nazarian, R., Shi, H., Wang, Q. et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
76. Newton, A.C. (2003). Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem. J. 370, 361-371.
77. Nishikawa, K., Toker, A., Johannes, F.J., Songyang, Z., and Cantley, L.C. (1997). Determination of the specific substrate sequence motifs of protein kinase C isozymes. J. Biol. Chem. 272, 952-960.
78. Nishizuka, Y. (1992). Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258, 607-614.
79. Obeid, L.M., Blobe, G.C., Karolak, L.A., and Hannun, Y.A. (1992). Cloning and characterization of the major promoter of the human protein kinase C β gene. Regulation by phorbol esters. J. Biol. Chem. 267, 20804-20810.
80. O'Connell, M.P., Fiori, J.L., Xu, M. et al. (2010). The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene 29, 34-44.
81. Oka, M., Ogita, K., Ando, H., Horikawa, T., Hayashibe, K., Saito, N., Kikkawa, U., and Ichihashi, M. (1996). Deletion of specific protein kinase C subspecies in human melanoma cells. J. Cell. Physiol. 167, 406-412.
82. Oka, M., Nishigori, C., Kageshita, T., Hsu, M.Y., Penmatcha, S., and Herlyn, M. (2006). Expression of PKC isoforms in human melanocytic cells in situ. J. Dermatol. Sci. 41, 157-161.
83. Oka, M., Kikkawa, U., and Nishigori, C. (2008). Protein kinase C-βII represses hepatocyte growth factor-induced invasion by preventing the association of adapter protein Gab1 and phosphatidylinositol 3-kinase in melanoma cells. J. Invest. Dermatol. 128, 188-195.
84. Ono, Y., Kurokawa, T., Fujii, T., Kawahara, K., Igarashi, K., Kikkawa, U., Ogita, K., and Nishizuka, Y. (1986). Two types of complementary DNAs of rat brain protein kinase C. Heterogeneity determined by alternative splicing. FEBS Lett. 206, 347-352.
85. Park, H.Y., Russakovsky, V., Ohno, S., and Gilchrest, B.A. (1993). The β isoform of protein kinase C stimulates human melanogenesis by activating tyrosinase in pigment cells. J. Biol. Chem. 268, 11742-11749.
86. Park, H.Y., Russakovsky, V., Ao, Y., Fernandez, E., and Gilchrest, B.A. (1996). Alpha-melanocyte stimulating hormone-induced pigmentation is blocked by depletion of protein kinase C. Exp. Cell Res. 227, 70-79.
87. Park, H.Y., Perez, J.M., Laursen, R., Hara, M., and Gilchrest, B.A. (1999). Protein kinase C-β activates tyrosinase by phosphorylating serine residues in its cytoplasmic domain. J. Biol. Chem. 274, 16470-16478.
88. Park, H.Y., Lee, J., Gonzalez, S., Middelkamp-Hup, M.A., Kapasi, S., Peterson, S., and Gilchrest, B.A. (2004a). Topical application of a protein kinase C inhibitor reduces skin and hair pigmentation. J. Invest. Dermatol. 122, 159-166.
89. Park, H.Y., Wu, H., Killoran, C.E., and Gilchrest, B.A. (2004b). The receptor for activated C-kinase-I (RACK-I) anchors activated PKC-β on melanosomes. J. Cell Sci. 117, 3659-3668.
90. Park, H.Y., Wu, C., Yonemoto, L., Murphy-Smith, M., Wu, H., Stachur, C.M., and Gilchrest, B.A. (2006). MITF mediates cAMP-induced protein kinase C-β expression in human melanocytes. Biochem. J. 395, 571-578.
91. Perego, C., Porro, D., and La Porta, C.A. (2002). Differential localisation of nPKCδ during cell cycle progression. Biochem. Biophys. Res. Commun. 294, 127-131.
92. Pinton, P., Rimessi, A., Marchi, S. et al. (2007). Protein kinase C β and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science, 315, 659-663.
93. Pittelkow, M.R., and Shipley, G.D. (1989). Serum-free culture of normal human melanocytes: growth kinetics and growth factor requirements. J. Cell. Physiol. 140, 565-576.
94. Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M., and Rosen, N. (2010). RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430.
95. Poulikakos, P.I., Persaud, Y., Janakiraman, M. et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 480, 387-390.
96. Powell, M.B., Rosenberg, R.K., Graham, M.J., Birch, M.L., Yamanishi, D.T., Buckmeier, J.A., and Meyskens Jr, F.L. (1993). Protein kinase C β expression in melanoma cells and melanocytes: differential expression correlates with biological responses to 12-O-tetradecanoylphorbol 13-acetate. J. Cancer Res. Clin. Oncol. 119, 199-206.
97. Propper, D.J., Macaulay, V., O'Byrne, K.J., Braybrooke, J.P., Wilner, S.M., Ganesan, T.S., Talbot, D.C., and Harris, A.L. (1998). A phase II study of bryostatin 1 in metastatic malignant melanoma. Br. J. Cancer 78, 1337-1341.
98. Putnam, A.J., Schulz, V.V., Freiter, E.M., Bill, H.M., and Miranti, C.K. (2009). Src, PKCα, and PKCδ are required for αvβ3 integrin-mediated metastatic melanoma invasion. Cell Commun. Signal. 7, 10.
99. Ramsay, J.R., Suhrbier, A., Aylward, J.H., Ogbourne, S., Cozzi, S.J., Poulsen, M.G., Baumann, K.C., Welburn, P., Redlich, G.L., and Parsons, P.G. (2011). The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers. Br. J. Dermatol. 164, 633-636.
100. Rizvi, M.A., Ghias, K., Davies, K.M., Ma, C., Weinberg, F., Munshi, H.G., Krett, N.L., and Rosen, S.T. (2006). Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol. Cancer Ther. 5, 1783-1789.
101. Ryu, B., Kim, D.S., Deluca, A.M., and Alani, R.M. (2007). Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS ONE 2, e594.
102. Sako, T., Yuspa, S.H., Herald, C.L., Pettit, G.R., and Blumberg, P.M. (1987). Partial parallelism and partial blockade by bryostatin 1 of effects of phorbol ester tumor promoters on primary mouse epidermal cells. Cancer Res. 47, 5445-5450.
103. Sanz-Navares, E., Fernandez, N., Kazanietz, M.G., and Rotenberg, S.A. (2001). Atypical protein kinase Cζ suppresses migration of mouse melanoma cells. Cell Growth Differ. 12, 517-524.
104. Schechtman, D., and Mochly-Rosen, D. (2001). Adaptor proteins in protein kinase C-mediated signal transduction. Oncogene 20, 6339-6347.
105. Schonwasser, D.C., Marais, R.M., Marshall, C.J., and Parker, P.J. (1998). Activation of the mitogen-activated protein kinase/extracellular signal- regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol. Cell. Biol. 18, 790-798.
106. Schuchter, L.M., Esa, A.H., May, S., Laulis, M.K., Pettit, G.R., and Hess, A.D. (1991). Successful treatment of murine melanoma with bryostatin 1. Cancer Res. 51, 682-687.
107. Scott, G.A., Arioka, M., and Jacobs, S.E. (2007). Lysophosphatidylcholine mediates melanocyte dendricity through PKCζ activation. J. Invest. Dermatol. 127, 668-675.
108. Selzer, E., Okamoto, I., Lucas, T., Kodym, R., Pehamberger, H., and Jansen, B. (2002). Protein kinase C isoforms in normal and transformed cells of the melanocytic lineage. Melanoma Res. 12, 201-209.
109. Sharma, G.D., Ottino, P., Bazan, N.G., and Bazan, H.E. (2005). Epidermal and hepatocyte growth factors, but not keratinocyte growth factor, modulate protein kinase Calpha translocation to the plasma membrane through 15(S)-hydroxyeicosatetraenoic acid synthesis. J. Biol. Chem. 280, 7917-7924.
110. Sharma, G.D., Kakazu, A., and Bazan, H.E. (2007). Protein kinase C alpha and epsilon differentially modulate hepatocyte growth factor-induced epithelial proliferation and migration. Exp. Eye Res. 85, 289-297.
111. Siller, G., Gebauer, K., Welburn, P., Katsamas, J., and Ogbourne, S.M. (2009). PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas. J. Dermatol. 50, 16-22.
112. Siller, G., Rosen, R., Freeman, M., Welburn, P., Katsamas, J., and Ogbourne, S.M. (2010). PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas. J. Dermatol. 51, 99-105.
113. Solit, D.B., and Rosen, N. (2011). Resistance to BRAF inhibition in melanomas. N. Engl. J. Med. 364, 772-774.
114. Sosman, J.A., Kim, K.B., Schuchter, L. et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714.
115. de Souza, G.A., Godoy, L.M., Teixeira, V.R. et al. (2006). Proteomic and SAGE profiling of murine melanoma progression indicates the reduction of proteins responsible for ROS degradation. Proteomics 6, 1460-1470.
116. Stahl, J.M., Cheung, M., Sharma, A., Trivedi, N.R., Shanmugam, S., and Robertson, G.P. (2003). Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 63, 2881-2890.
117. Staudt, M.R., Depass, A.L., Sarkar, D., and Fisher, P.B. (2008). Model cell culture system for defining the molecular and biochemical events mediating terminal differentiation of human melanoma cells. J. Cell. Physiol. 218, 304-314.
118. Stebbins, E.G., and Mochly-Rosen, D. (2001). Binding specificity for RACK1 resides in the V5 region of βII protein kinase C. J. Biol. Chem. 276, 29644-29650.
119. Swope, V.B., Medrano, E.E., Smalara, D., and Abdel-Malek, Z.A. (1995). Long-term proliferation of human melanocytes is supported by the physiologic mitogens alpha-melanotropin, endothelin-1, and basic fibroblast growth factor. Exp. Cell Res. 217, 453-459.
120. Szalay, J., Bruno, P., Bhati, R., Adjodha, J., Schueler, D., Summerville, V., and Vazeos, R. (2001). Associations of PKC isoforms with the cytoskeleton of B16F10 melanoma cells. J. Histochem. Cytochem. 49, 49-66.
121. Szallasi, Z., Smith, C.B., Pettit, G.R., and Blumberg, P.M. (1994). Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J. Biol. Chem. 269, 2118-2124.
122. Szallasi, Z., Kosa, K., Smith, C.B., Dlugosz, A.A., Williams, E.K., Yuspa, S.H., and Blumberg, P.M. (1995). Differential regulation by anti-tumor-promoting 12-deoxyphorbol- 13-phenylacetate reveals distinct roles of the classical and novel protein kinase C isozymes in biological responses of primary mouse keratinocytes. Mol. Pharmacol. 47, 258-265.
123. Szallasi, Z., Du, L., Levine, R., Lewin, N.E., Nguyen, P.N., Williams, M.D., Pettit, G.R., and Blumberg, P.M. (1996). The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1. Cancer Res. 56, 2105-2111.
124. Teicher, B.A., Alvarez, E., Menon, K., Esterman, M.A., Considine, E., Shih, C., and Faul, M.M. (2002). Antiangiogenic effects of a protein kinase C β-selective small molecule. Cancer Chemother. Pharmacol. 49, 69-77.
125. Teng, D.H., Hu, R., Lin, H. et al. (1997). MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 57, 5221-5225.
126. Tozer, R.G., Burdette-Radoux, S., Berlanger, K., Davis, M.L., Lohmann, R.C., Rusthoven, J.R., Wainman, N., Zee, B., and Seymour, L. (2002). A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study. Invest. New Drugs 20, 407-412.
127. Ueda, Y., Hirai, S., Osada, S., Suzuki, A., Mizuno, K., and Ohno, S. (1996). Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J. Biol. Chem. 271, 23512-23519.
128. Van Raamsdonk, C.D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O'Brien, J.M., Simpson, E.M., Barsh, G.S., and Bastian, B.C. (2009). Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457, 599-602.
129. Van Raamsdonk, C.D., Griewank, K.G., Crosby, M.B. et al. (2010). Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 363, 2191-2199.
130. Villanueva, J., Vultur, A., Lee, J.T. et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695.
131. Voris, J.P., Sitailo, L.A., Rahn, H.R., Defnet, A., Gerds, A.T., Sprague, R., Yadav, V., Caroline, L.P.I., and Denning, M.F. (2010). Functional alterations in protein kinase C beta II expression in melanoma. Pigment Cell Melanoma Res. 23, 216-224.
132. Wagle, N., Emery, C., Berger, M.F. et al. (2011). Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085-3096.
133. Wang, Q.J., Bhattacharyya, D., Garfield, S., Nacro, K., Marquez, V.E., and Blumberg, P.M. (1999). Differential localization of protein kinase C delta by phorbol esters and related compounds using a fusion protein with green fluorescent protein. J. Biol. Chem. 274, 37233-37239.
134. Wang, Q.J., Fang, T.W., Fenick, D., Garfield, S., Bienfait, B., Marquez, V.E., and Blumberg, P.M. (2000). The lipophilicity of phorbol esters as a critical factor in determining the pattern of translocation of protein kinase C delta fused to green fluorescent protein. J. Biol. Chem. 275, 12136-12146.
135. Wang, G., Silva, J., Krishnamurthy, K., Tran, E., Condie, B.G., and Bieberich, E. (2005). Direct binding to ceramide activates protein kinase Cζ before the formation of a pro-apoptotic complex with PAR-4 in differentiating stem cells. J. Biol. Chem. 280, 26415-26424.
136. Weeraratna, A.T., Jiang, Y., Hostetter, G., Rosenblatt, K., Duray, P., Bittner, M., and Trent, J.M. (2002). Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1, 279-288.
137. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338-2342.
138. Wolff, R.A., Fuchs, M., Di Bartolomeo, M., Hossain, A.M., Stoffregen, C., Nicol, S., and Heinemann, V. (2011). A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer. Cancer doi: 10.1002/cncr.26692.
139. Wu, X., Zhu, M., Fletcher, J.A., Giobbie-Hurder, A., and Hodi, F.S. (2012). The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS ONE 7, e29622.
140. Xia, P., Aiello, L.P., Ishii, H., Jiang, Z.Y., Park, D.J., Robinson, G.S., Takagi, H., Newsome, W.P., Jirousek, M.R., and King, G.L. (1996). Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. 98, 2018-2026.
141. Yadav, V., Yanez, N.C., Fenton, S.E., and Denning, M.F. (2010). Loss of protein kinase C δ gene expression in human squamous cell carcinomas: a laser capture microdissection study. Am. J. Pathol. 176, 1091-1096.
142. Yamanishi, D.T., Graham, M., Buckmeier, J.A., and Meyskens Jr, F.L. (1991). The differential expression of protein kinase C genes in normal human neonatal melanocytes and metastatic melanomas. Carcinogenesis 12, 105-109.
143. Zaidi, M.R., Day, C.P., and Merlino, G. (2008). From UVs to metastases: modeling melanoma initiation and progression in the mouse. J. Invest. Dermatol. 128, 2381-2391.
144. Zhang, X.M., Chen, J., Xia, Y.G., and Xu, Q. (2005). Apoptosis of murine melanoma B16-BL6 cells induced by quercetin targeting mitochondria, inhibiting expression of PKC-α and translocating PKC-δ. Cancer Chemother. Pharmacol. 55, 251-262.